XPERT TECHNOLOGIES Revenue and Competitors

Kuala Lumpur, MY

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • XPERT TECHNOLOGIES's estimated annual revenue is currently $2M per year.(i)
  • XPERT TECHNOLOGIES's estimated revenue per employee is $101,500

Employee Data

  • XPERT TECHNOLOGIES has 20 Employees.(i)

XPERT TECHNOLOGIES's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$158.8M79367%$68MN/A
#2
$514.6M248279%$343.2M$10B
#3
$3.4M33-6%N/AN/A
#4
$0.6M8N/AN/AN/A
#5
$4.1M35N/AN/AN/A
#6
$0.5M148%$11.7MN/A
#7
$5.7M49N/AN/AN/A
#8
$2.8M28N/AN/AN/A
#9
$1.7M1958%N/AN/A
#10
$1.6M0N/A$54.8MN/A
#11
$0.3M4N/AN/AN/A
#12
$5.6M48N/AN/AN/A
#13
$0.5M7N/AN/AN/A
#14
$2.1M29-37%$21MN/A
#15
$5.3M46N/AN/AN/A
#16
$3.9M34N/AN/AN/A
#17
$35.1M2252%$2.6MN/A
#18
$2.1M21N/AN/AN/A
#19
$0.3M4N/AN/AN/A
#20
$0.3M4N/AN/AN/A
Add Company

What Is XPERT TECHNOLOGIES?

keywords:N/A

N/A

Total Funding

20

Number of Employees

$2M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

XPERT TECHNOLOGIES News

2022-04-17 - Molecular tests for TB: A Cochrane review

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: Global rollout of rapid molecular tests ...

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: A Cochrane review

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: Global rollout of rapid molecular tests ...

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M2033%N/A
#2
$2M20-9%N/A
#3
$2.1M21N/AN/A
#4
$2.1M21-16%N/A
#5
$3.2M21-36%N/A